AXSM Earnings Axsome Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–22 of 22
| Q2 2026 | 2026-06-30 | -2.25 | 2026-08-10 | 10-Q |
| Q1 2026 | 2026-03-31 | -1.26 | 2026-05-04 | 10-Q |
| FY 2025 | 2025-12-31 | -3.68 | 2026-02-23 | 10-K |
| Q3 2025 | 2025-09-30 | -3.13 | 2025-11-03 | 10-Q |
| Q2 2026 | 2025-06-30 | -2.18 | 2026-08-10 | 10-Q |
| Q1 2026 | 2025-03-31 | -1.22 | 2026-05-04 | 10-Q |
| FY 2025 | 2024-12-31 | -5.99 | 2026-02-23 | 10-K |
| Q3 2025 | 2024-09-30 | -4.45 | 2025-11-03 | 10-Q |
| Q2 2025 | 2024-06-30 | -3.11 | 2025-08-04 | 10-Q |
| Q1 2025 | 2024-03-31 | -1.44 | 2025-05-05 | 10-Q |
| FY 2025 | 2023-12-31 | -5.27 | 2026-02-23 | 10-K |
| Q3 2024 | 2023-09-30 | -3.14 | 2024-11-12 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.80 | 2024-08-05 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.26 | 2024-05-06 | 10-Q |
| FY 2024 | 2022-12-31 | -4.60 | 2025-02-18 | 10-K |
| Q3 2023 | 2022-09-30 | -3.17 | 2023-11-06 | 10-Q |
| Q2 2023 | 2022-06-30 | -2.09 | 2023-08-07 | 10-Q |
| Q2 2023 | 2022-03-31 | -1.06 | 2023-08-07 | 10-Q |
| FY 2023 | 2021-12-31 | -3.47 | 2024-02-23 | 10-K |
| Q3 2022 | 2021-09-30 | -2.57 | 2022-11-07 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.64 | 2022-08-09 | 10-Q |
| FY 2022 | 2020-12-31 | -2.77 | 2023-02-28 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.